Gastroparesis
Nortriptyline for idiopathic gastroparesis: a multicenter, randomized, double-masked, placebo-controlled trial
IRB number: HUM00021678
Enrollment Status: OPEN
The purpose of this study is to find out whether treatment with the medication nortriptyline is better than a placebo in improving the symptoms of gastroparesis – specifically, the type of gastroparesis called "idiopathic," which means "of unknown cause or origin." Nortriptyline is approved by the United States Food and Drug Administration for treatment of depression. It is not currently approved for treating symptoms of gastroparesis.
Eligibility
Age Range: From 21 to 65 years
Gender: Male & female
Ethnicity: All
Race: All
Smoking: Both smoking and non-smoking volunteers
Medication: Not taking medication
Study population: patients with symptoms of gastroparesis
Other Eligibility Factors
- Documentation of delayed gastric emptying within 2 years.
- Negative upper endoscopy or upper GI series within 2 years of registration date.
- Symptoms of gastroparesis for at least 6 months (does not have to be contiguous)
Prinicipal Investigator:
- William L Hasler, MD
Contact:
- Nara Wootten 734-615-6723 or e-mail: smao@med.umich.edu
This clinical study is sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). For more information provided by NIDDK, click on the following link: Nortriptyline for Idiopathic Gastroparesis
